312 related articles for article (PubMed ID: 15546908)
1. Toward the development of a test for growth hormone (GH) abuse: a study of extreme physiological ranges of GH-dependent markers in 813 elite athletes in the postcompetition setting.
Healy ML; Dall R; Gibney J; Bassett E; Ehrnborg C; Pentecost C; Rosen T; Cittadini A; Baxter RC; Sönksen PH
J Clin Endocrinol Metab; 2005 Feb; 90(2):641-9. PubMed ID: 15546908
[TBL] [Abstract][Full Text] [Related]
2. The growth hormone/insulin-like growth factor-I axis hormones and bone markers in elite athletes in response to a maximum exercise test.
Ehrnborg C; Lange KH; Dall R; Christiansen JS; Lundberg PA; Baxter RC; Boroujerdi MA; Bengtsson BA; Healey ML; Pentecost C; Longobardi S; Napoli R; Rosén T;
J Clin Endocrinol Metab; 2003 Jan; 88(1):394-401. PubMed ID: 12519882
[TBL] [Abstract][Full Text] [Related]
3. Influence of demographic factors and sport type on growth hormone-responsive markers in elite athletes.
Nelson AE; Howe CJ; Nguyen TV; Leung KC; Trout GJ; Seibel MJ; Baxter RC; Handelsman DJ; Kazlauskas R; Ho KK
J Clin Endocrinol Metab; 2006 Nov; 91(11):4424-32. PubMed ID: 16912136
[TBL] [Abstract][Full Text] [Related]
4. Elite volunteer athletes of different sport disciplines may have elevated baseline GH levels divorced from unaltered levels of both IGF-I and GH-dependent bone and collagen markers: a study on-the-field.
Sartorio A; Marazzi N; Agosti F; Faglia G; Corradini C; De Palo E; Cella S; Rigamonti A; Muller EE
J Endocrinol Invest; 2004 May; 27(5):410-5. PubMed ID: 15279071
[TBL] [Abstract][Full Text] [Related]
5. Serum insulin-like growth factor-I and pro-collagen type III N-terminal peptide in adolescent elite athletes: implications for the detection of growth hormone abuse in sport.
Guha N; Erotokritou-Mulligan I; Burford C; Strobridge G; Brigg J; Drake T; Bassett EE; Cowan D; Bartlett C; Sönksen PH; Holt RI
J Clin Endocrinol Metab; 2010 Jun; 95(6):2969-76. PubMed ID: 20410221
[TBL] [Abstract][Full Text] [Related]
6. Biochemical markers of recombinant human insulin-like growth factor-I (rhIGF-I)/rhIGF binding protein-3 (rhIGFBP-3) misuse in athletes.
Guha N; Erotokritou-Mulligan I; Nevitt SP; Francis M; Bartlett C; Cowan DA; Bassett EE; Sönksen PH; Holt RI
Drug Test Anal; 2013; 5(11-12):843-9. PubMed ID: 24173773
[TBL] [Abstract][Full Text] [Related]
7. Immunoassays for the measurement of IGF-II, IGFBP-2 and -3, and ICTP as indirect biomarkers of recombinant human growth hormone misuse in sport. Values in selected population of athletes.
Abellan R; Ventura R; Palmi I; di Carlo S; Bacosi A; Bellver M; Olive R; Pascual JA; Pacifici R; Segura J; Zuccaro P; Pichini S
J Pharm Biomed Anal; 2008 Nov; 48(3):844-52. PubMed ID: 18617352
[TBL] [Abstract][Full Text] [Related]
8. The development of decision limits for the implementation of the GH-2000 detection methodology using current commercial insulin-like growth factor-I and amino-terminal pro-peptide of type III collagen assays.
Erotokritou-Mulligan I; Guha N; Stow M; Bassett EE; Bartlett C; Cowan DA; Sönksen PH; Holt RI
Growth Horm IGF Res; 2012 Apr; 22(2):53-8. PubMed ID: 22305721
[TBL] [Abstract][Full Text] [Related]
9. Demographic factors influencing the GH system: Implications for the detection of GH doping in sport.
Nelson AE; Ho KK
Growth Horm IGF Res; 2009 Aug; 19(4):327-32. PubMed ID: 19481485
[TBL] [Abstract][Full Text] [Related]
10. Responses of the growth hormone (GH) and insulin-like growth factor axis to exercise, GH administration, and GH withdrawal in trained adult males: a potential test for GH abuse in sport.
Wallace JD; Cuneo RC; Baxter R; Orskov H; Keay N; Pentecost C; Dall R; Rosén T; Jørgensen JO; Cittadini A; Longobardi S; Sacca L; Christiansen JS; Bengtsson BA; Sönksen PH
J Clin Endocrinol Metab; 1999 Oct; 84(10):3591-601. PubMed ID: 10523001
[TBL] [Abstract][Full Text] [Related]
11. No evidence of insulin-like growth factor-binding protein 3 proteolysis during a maximal exercise test in elite athletes.
Dall R; Lange KH; Kjaer M; Jørgensen JO; Christiansen JS; Orskov H; Flyvbjerg A
J Clin Endocrinol Metab; 2001 Feb; 86(2):669-74. PubMed ID: 11158029
[TBL] [Abstract][Full Text] [Related]
12. Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease.
Fernholm R; Bramnert M; Hägg E; Hilding A; Baylink DJ; Mohan S; Thorén M
J Clin Endocrinol Metab; 2000 Nov; 85(11):4104-12. PubMed ID: 11095440
[TBL] [Abstract][Full Text] [Related]
13. Intra-individual variation of GH-dependent markers in athletes: comparison of population based and individual thresholds for detection of GH abuse in sports.
Kniess A; Ziegler E; Thieme D; Müller RK
J Pharm Biomed Anal; 2013 Oct; 84():201-8. PubMed ID: 23850935
[TBL] [Abstract][Full Text] [Related]
14. The development of decision limits for the GH-2000 detection methodology using additional insulin-like growth factor-I and amino-terminal pro-peptide of type III collagen assays.
Holt RI; Böhning W; Guha N; Bartlett C; Cowan DA; Giraud S; Bassett EE; Sönksen PH; Böhning D
Drug Test Anal; 2015 Sep; 7(9):745-55. PubMed ID: 25645199
[TBL] [Abstract][Full Text] [Related]
15. The effect of sports injury on insulin-like growth factor-I and type 3 procollagen: implications for detection of growth hormone abuse in athletes.
Erotokritou-Mulligan I; Bassett EE; Bartlett C; Cowan D; McHugh C; Seah R; Curtis B; Wells V; Harrison K; Sönksen PH; Holt RI;
J Clin Endocrinol Metab; 2008 Jul; 93(7):2760-3. PubMed ID: 18413420
[TBL] [Abstract][Full Text] [Related]
16. Effect of physical fitness and endurance exercise on indirect biomarkers of growth hormone and insulin misuse: Immunoassay-based measurement in urine samples.
Pichini S; Ventura R; Palmi I; di Carlo S; Bacosi A; Langohr K; Abellan R; Pascual JA; Pacifici R; Segura J; Zuccaro P
J Pharm Biomed Anal; 2010 Dec; 53(4):1003-10. PubMed ID: 20674210
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamics of growth hormone abuse biomarkers and the influence of gender and testosterone: a randomized double-blind placebo-controlled study in young recreational athletes.
Nelson AE; Meinhardt U; Hansen JL; Walker IH; Stone G; Howe CJ; Leung KC; Seibel MJ; Baxter RC; Handelsman DJ; Kazlauskas R; Ho KK
J Clin Endocrinol Metab; 2008 Jun; 93(6):2213-22. PubMed ID: 18381573
[TBL] [Abstract][Full Text] [Related]
18. Effects of intensive chemotherapy on bone and collagen turnover and the growth hormone axis in children with acute lymphoblastic leukemia.
Crofton PM; Ahmed SF; Wade JC; Stephen R; Elmlinger MW; Ranke MB; Kelnar CJ; Wallace WH
J Clin Endocrinol Metab; 1998 Sep; 83(9):3121-9. PubMed ID: 9745414
[TBL] [Abstract][Full Text] [Related]
19. Responses of markers of bone and collagen turnover to exercise, growth hormone (GH) administration, and GH withdrawal in trained adult males.
Wallace JD; Cuneo RC; Lundberg PA; Rosén T; Jørgensen JO; Longobardi S; Keay N; Sacca L; Christiansen JS; Bengtsson BA; Sönksen PH
J Clin Endocrinol Metab; 2000 Jan; 85(1):124-33. PubMed ID: 10634375
[TBL] [Abstract][Full Text] [Related]
20. Effect of physical fitness and endurance exercise on indirect biomarkers of recombinant growth hormone misuse: insulin-like growth factor I and procollagen type III peptide.
Abellan R; Ventura R; Pichini S; Di Giovannandrea R; Bellver M; Olive R; Pacifici R; Pascual JA; Zuccaro P; Segura J
Int J Sports Med; 2006 Dec; 27(12):976-83. PubMed ID: 16612742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
